Biomarkers to define the treatment end-point for pulmonary exacerbations in cystic fibrosis

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/GNT1126973

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Sensitive and reliable tests are required to monitor lung disease severity in cystic fibrosis. A number of potential methods have emerged in recent years. We will investigate how these tests track an acute episode of lung disease and determine whether, following a typical course of treatment, there is evidence of residual damage that contributes to overall progression of lung disease.

Funded Activity Details

Start Date: 01-01-2017

End Date: 01-01-2021

Funding Scheme: Project Grants

Funding Amount: $1,031,371.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Systems Physiology

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

cystic fibrosis | diagnostic imaging | exacerbation | inflammation | metabolomics

Related Links